Gamelin Erick
Chief Development Officer
Gamelin Erick has filed 5 SEC Form 4 filings (5 transaction rows) across 1 company, with disclosures dating back to 2025. 5 of those filings fall inside the rolling window. Most recent filing: Aug 20, 2026.
On the most recent filing, Gamelin Erick is listed as Chief Development Officer at Acrivon Therapeutics, Inc. Inside the rolling window, Gamelin Erick reported no open-market purchases and 1 open-market sale totaling $804 in ACRV.
Companies traded
Other insiders at ACRV
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$804
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Gamelin Erick made?
Gamelin Erick has filed 5 SEC Form 4 filings (5 transaction rows) across 1 company since 2025.
Which companies does Gamelin Erick trade?
Gamelin Erick has filed SEC Form 4 disclosures for 1 company, including ACRV.
When was Gamelin Erick's most recent SEC Form 4 filing?
Gamelin Erick's most recent SEC Form 4 filing on Tracefour is dated Aug 20, 2026.
What is Gamelin Erick's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Gamelin Erick is listed as Chief Development Officer.
What is Gamelin Erick's total buy and sell value in the current window?
Inside the rolling retention window, Gamelin Erick bought $0 and sold $804 based on SEC Form 4 filings.
What was Gamelin Erick's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 400 ACRV shares on 2026-08-18, worth $804, per SEC Form 4 filings.